Main Number of contacts with foreign regulators to discuss scientific, ethical or safety issues related to pediatrics in the month Pediatric studies are usually global given the limited number of sick children, particularly those afflicted with chronic disease. Given the global nature of pediatric trials, it is critical that FDA expand its global outreach to include other regulatory entities that oversee pediatric trials. International scientific communication and collaboration will enhance the safety, ethics and scientific rigor of pediatric studies, thus preventing children from becoming a commodity on the global market for economic gain. A "contact" refers to written or oral communication between FDA and foreign regulators on matters involving pediatric issues. E-mail is an example of written communication and a teleconference, as oral communication. <i>Information is current as of December 31, 2012.</i> Number of Contacts column 2010 FY 2010 Total: 138 2011 FY 2011 Total: 169 2012 FY 2012 YTD: 327 2013 FY 2013 YTD: 81 Sub Number of contacts with foreign regulators to discuss scientific, ethical or safety issues related to pediatrics in the month Number of oral communications with foreign regulators on drug products in the month (1) (1) Tracking against this measure did not begin until November 2011. column 2012 FY 2012 Total: 55 2013 FY 2013 YTD: 10 Sub Number of contacts with foreign regulators to discuss scientific, ethical or safety issues related to pediatrics in the month Number of written exchanges with foreign regulators on drug products in the month (1) (1) Tracking against this measure did not begin until November 2011. column 2012 FY 2012 YTD: 260 2013 FY 2013 YTD: 71 http://www.fda.gov/AboutFDA/Transparency/track/ucm206293.htm FDA-TRACK Office of Special Medical Programs Dashboard ਍††਍਍਍਍਍਍਍